Haleos Labs Limi

What does SMS Lifesciences do?

SMS Lifesciences India Ltd is a micro-cap company in the pharmaceuticals and biotechnology sector, reporting net sales of 89 Cr and a net profit of 3 Cr for March 2025. The company focuses on pharmaceutical development and has a market cap of Rs 392 Cr.

Overview:<BR>SMS Lifesciences India Ltd operates in the pharmaceuticals and biotechnology industry and is categorized as a micro-cap company.<BR><BR>History:<BR>The company was originally incorporated as "Potluri Real Estate Private Limited" in 2006, underwent several name changes, and became "SMS Lifesciences India Private Limited" in 2014 to focus on the pharma sector. The latest quarterly results reported net sales and profit for March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 89 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 3 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 392 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 19.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.12%<BR>- Debt-Equity: 0.43<BR>- Return on Equity: 10.23%<BR>- Price to Book: 1.97<BR><BR>Contact Details:<BR>Address: Plot No 19-III Road No 71, Opp Bharatiya Vidya Bhavan PSc Hyderabad Telangana : 500096 <BR>Tel: 91-040-6628-8888 <BR>Email: info@smslife.in <BR>Website: http://www.smslife.in

Has SMS Lifesciences declared dividend?

Yes, SMS Lifesciences India Ltd has declared a 15% dividend, amounting to ₹1.5 per share, with an ex-date of September 23, 2024. The company has shown strong price appreciation over various periods, with total returns reaching 353.05% over the last 5 years.

SMS Lifesciences India Ltd has declared a 15% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 15%<BR>- Amount per share: 1.5<BR>- Ex-date: 23 Sep 24<BR><BR>Dividend Yield: 0.12%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 11.55%, with a dividend return of 0%, resulting in a total return of 11.55%.<BR><BR>Over the past year, the price return reached 68.95%, while the dividend return was 0.19%, leading to a total return of 69.14%.<BR><BR>In the 2-year period, the price return was 146.28%, with a dividend return of 0.56%, culminating in a total return of 146.84%.<BR><BR>For the 3-year period, the price return stood at 83.85%, with a dividend return of 0.67%, resulting in a total return of 84.52%.<BR><BR>In the last 4 years, the price return was 105.78%, while the dividend return was 0.75%, leading to a total return of 106.53%.<BR><BR>Over the past 5 years, the price return was 351.06%, with a dividend return of 1.99%, resulting in a total return of 353.05%.<BR><BR>Overall, SMS Lifesciences has declared a dividend, contributing to a modest dividend yield, while the total returns over various periods indicate strong price appreciation, particularly over the longer term.

Who are the peers of the SMS Lifesciences?

SMS Lifesciences' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Zenotech Lab, Oxygenta Pharma, Fredun Pharma, and Trident Lifeline. While SMS Lifesciences has average management risk and capital structure, its 1-year return of 68.63% is notably higher than Fredun Pharma's -8.48%.

Peers: The peers of SMS Lifesciences are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Zenotech Lab., Oxygenta Pharma, Fredun Pharma, and Trident Lifeline.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at SMS Lifesciences, Zenotech Lab., Fredun Pharma, and Trident Lifeline. Growth is excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while below average growth is seen at Divi's Lab., SMS Lifesciences, Zenotech Lab., and Torrent Pharma, with Fredun Pharma showing good growth. Capital structure is excellent for Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while SMS Lifesciences has an average capital structure, with Zenotech Lab. rated good, and Fredun Pharma rated below average.<BR><BR>Return Snapshot: Oxygenta Pharma has the highest 1-year return at 169.57%, while Fredun Pharma has the lowest at -8.48%, and SMS Lifesciences' 1-year return of 68.63% is significantly higher than Fredun Pharma's. Additionally, the six-month returns are negative for Zenotech Lab. and Fredun Pharma.

Is SMS Lifesciences overvalued or undervalued?

As of May 30, 2025, SMS Lifesciences is considered undervalued with an attractive valuation grade, strong financial metrics, and a 67.7% return over the past year, significantly outperforming the Sensex.

As of 30 May 2025, the valuation grade for SMS Lifesciences has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued based on its strong financial metrics, including a PE ratio of 19.39, an EV to EBITDA ratio of 10.55, and a PEG ratio of 0.16, which suggests significant growth potential relative to its price. <BR><BR>In comparison to its peers, SMS Lifesciences stands out with a similar PE ratio to its closest competitor, while also demonstrating a more favorable PEG ratio, indicating that it may offer better growth prospects at its current valuation. Notably, the company's return over the past year has significantly outperformed the Sensex, with a remarkable 67.7% increase compared to the index's 7.57%. This performance reinforces the argument for its undervaluation in the market.

What is the technical trend for SMS Lifesciences?

As of June 5, 2025, SMS Lifesciences shows a mildly bearish trend due to bearish daily moving averages and a weak weekly RSI, despite some bullish signals from the MACD and KST on longer time frames.

As of 5 June 2025, the technical trend for SMS Lifesciences has changed from mildly bullish to mildly bearish. The weekly MACD remains bullish, but the monthly MACD is mildly bearish, indicating a divergence in time frames. The weekly RSI is bearish, while the monthly RSI shows no signal, suggesting weakness in momentum. Daily moving averages are bearish, reinforcing the current negative sentiment. The Bollinger Bands indicate a mildly bullish stance on both weekly and monthly charts, but this is overshadowed by the bearish signals from the daily moving averages and the weekly RSI. The KST is bullish on both weekly and monthly time frames, providing some support. However, the OBV shows a mildly bearish trend on the weekly, contrasting with a bullish monthly outlook. Overall, the current stance is mildly bearish, driven primarily by the bearish daily moving averages and the weekly RSI.

Who are in the management team of SMS Lifesciences?

As of March 2022, the management team of SMS Lifesciences includes T V V S N Murthy (Managing Director), P Sarath Kumar, Mannam Malakondaiah, Srinivas Samavedam, and P Venkata Subbarao (Independent Directors), Trupti Ranjan Mohanty (Company Secretary & Compliance Officer), Talluri Venkata Praveen (Executive Director), and Sudeepthi Gopin eedi (Whole-time Director). These members are responsible for the company's governance and operations.

As of March 2022, the management team of SMS Lifesciences includes the following individuals:<BR><BR>1. T V V S N Murthy - Managing Director<BR>2. P Sarath Kumar - Independent Director<BR>3. Trupti Ranjan Mohanty - Company Secretary & Compliance Officer<BR>4. Talluri Venkata Praveen - Executive Director<BR>5. Sudeepthi Gopin eedi - Whole-time Director<BR>6. Mannam Malakondaiah - Independent Director<BR>7. Srinivas Samavedam - Independent Director<BR>8. P Venkata Subbarao - Independent Director<BR><BR>These individuals play key roles in the governance and operational management of the company.

Who are the top shareholders of the SMS Lifesciences?

The top shareholder of SMS Lifesciences is Annapurna Talluri, holding 24.56%. Individual investors own 25.55%, while the highest public shareholder is Harita Projects Private with 1.57%.

The top shareholders of SMS Lifesciences include the promoters, with Annapurna Talluri holding the largest stake at 24.56%. There are no pledged promoter holdings, and mutual funds and foreign institutional investors do not hold any shares in the company. Additionally, the highest public shareholder is Harita Projects Private, which holds 1.57%. Individual investors collectively own 25.55% of the shares.

How big is SMS Lifesciences?

As of 24th July, SMS Lifesciences India Ltd has a market capitalization of 369.00 Cr, with recent net sales of 344.72 Cr and a net profit of 20.11 Cr. The balance sheet for March 2024 shows shareholder's funds of 176.81 Cr and total assets of 390.52 Cr.

As of 24th July, SMS Lifesciences India Ltd has a market capitalization of 369.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, SMS Lifesciences reported Net Sales of 344.72 Cr and a Net Profit of 20.11 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 176.81 Cr and Total Assets of 390.52 Cr.

When is the next results date for SMS Lifesciences?

The next results date for SMS Lifesciences is 11 August 2025.

The next results date for SMS Lifesciences is scheduled for 11 August 2025.

Are SMS Lifesciences latest results good or bad?

SMS Lifesciences' latest results show a net profit increase of 46.63% quarter-on-quarter, but revenue declined slightly by 1.37%, indicating mixed performance. While profitability improved, concerns about sluggish revenue growth and a below-average return on equity suggest challenges ahead.

The latest results for SMS Lifesciences present a mixed picture. On the positive side, the company reported a net profit of ₹6.10 crores for Q2 FY26, which is a significant increase of 46.63% compared to the previous quarter and a 30.62% rise year-on-year. Additionally, the operating margin improved to 16.69%, marking the highest level in eight quarters, indicating effective cost management.<BR><BR>However, there are concerns regarding revenue growth, as net sales slightly declined by 1.37% quarter-on-quarter and showed only a modest year-on-year growth of 3.71%. This suggests that while the company is improving its profitability through better margins, its top-line growth remains sluggish, which could indicate challenges in market demand or pricing power.<BR><BR>Moreover, the return on equity (ROE) stands at 10.23%, which is below industry standards, highlighting ongoing issues with capital efficiency. Overall, while the margin expansion and profit growth are encouraging, the muted revenue performance and weak return metrics suggest that the results are not entirely positive. Investors should weigh these factors carefully when assessing the company's performance and future prospects.

Should I buy, sell or hold Haleos Labs Limi?

How has been the historical performance of Haleos Labs Limi?

Haleos Labs Limi showed improved financial performance in Mar'25, with net sales rising to 344.72 Cr and profit after tax increasing to 18.73 Cr, up from 6.33 Cr in the previous year. The company also reported enhanced operational efficiency, reflected in a significant rise in operating profit to 49.90 Cr.

Answer:<BR>The historical performance of Haleos Labs Limi shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Haleos Labs Limi's net sales increased from 305.96 Cr in Mar'24 to 344.72 Cr in Mar'25, following a dip in Mar'23. The total operating income also rose to 344.72 Cr in Mar'25 from 305.96 Cr in the previous year. The raw material costs slightly decreased to 149.91 Cr in Mar'25, while employee costs rose to 59.54 Cr, reflecting a growing workforce. Total expenditure, excluding depreciation, increased to 299.68 Cr in Mar'25 from 274.84 Cr in Mar'24. Operating profit (PBDIT) saw a significant rise to 49.90 Cr in Mar'25, up from 34.95 Cr in Mar'24, indicating improved operational efficiency. Profit before tax surged to 26.19 Cr in Mar'25, compared to 9.85 Cr in the prior year, leading to a profit after tax of 18.73 Cr, up from 6.33 Cr. The consolidated net profit also increased to 20.11 Cr in Mar'25 from 9.09 Cr in Mar'24. The company's total liabilities slightly decreased to 389.99 Cr in Mar'25 from 391.33 Cr in Mar'24, while total assets also saw a decline to 389.99 Cr. Cash flow from operating activities improved to 34.00 Cr in Mar'25, up from 24.00 Cr in Mar'24, indicating better cash generation from core operations. Overall, Haleos Labs Limi demonstrated a positive trend in profitability and operational performance in the latest fiscal year.

Which are the latest news on Haleos Labs Limi?

Why is Haleos Labs Limited falling/rising?

As of 18-Jan, Haleos Labs Limited's stock price is rising to 1,335.00, reflecting a 1.23% increase. This rise is driven by strong recent financial results, positive investor sentiment, and the stock's performance above key moving averages, despite a significant drop in delivery volume.

As of 18-Jan, Haleos Labs Limited's stock price is rising, currently at 1,335.00, reflecting an increase of 16.2 (1.23%). This upward movement can be attributed to several factors. The stock has outperformed its sector by 2.34% today and has shown a consecutive gain over the last three days, with a total return of 5.95% during this period. Additionally, Haleos Labs is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong bullish trend.<BR><BR>Despite some negative indicators, such as a significant drop in delivery volume by 60.32% against the 5-day average, the overall performance metrics suggest a positive sentiment among investors. The company has recently reported positive results after two consecutive negative quarters, with a remarkable growth in profit before tax (PBT) of 203.38%. Furthermore, the company's low debt-equity ratio of 0.34 times and a high operating profit to interest ratio of 8.38 times contribute to a favorable financial outlook.<BR><BR>Overall, the combination of recent positive financial results, strong short-term performance, and favorable trading conditions has led to the rise in Haleos Labs Limited's stock price.